bioMérieux

BIM

FR0013280286

Medical Equipment, Supplies & Distribution

Market Closed - Euronext Paris Other stock markets 16:35:23 19/09/2024 BST			After market 18:48:50
108.20 ^EUR	+0.84%		108.40	+0.18%

09-18	BioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center At the Navy Yard in Philadelphia	CI
09-09	The market burns its idols

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Vous êtes déja client ? Log In

Latest news about bioMérieux

BioMérieux Celebrates the Opening of the Molecular and Genomic Innovation Center At the Navy Yard in Philadelphia	09-18	CI
The market burns its idols	09-09
BIOMÉRIEUX : Invest Securities raises its target	09-06	CF
BioMérieux S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	09-05	CI
Such a long wait	09-05
BIOMERIEUX : Q2 beat + guidance upgrade hailed by the markets	09-05
BioMérieux S.A., Q2 2024 Earnings Call, Sep 05, 2024	09-05
BIOMÉRIEUX : Oddo BHF confirms its recommendation	09-05	CF
BioMérieux raises its targets for 2024	09-05	CF
UBS Started Coverage of bioMérieux with Buy Rating	08-22	MT
BioMérieux: supported by a positive broker initiation	08-22	CF
BIOMÉRIEUX : UBS initiates buy coverage	08-22	CF
AlphaValue/Baader Europe Downgrades bioMérieux to Add, Reduces PT	08-21	MT
BioMérieux: a positive week, analysts optimistic	07-05	CF
Market Update-Europe closes higher on optimism about US rates	07-04	RE
TP ICAP Midcap Upgrades bioMérieux to Buy from Hold, Lifts PT	07-04	MT
Market Update-European stock markets rise in absence of Wall Street	07-04	RE
BioMérieux Announces USDA-FSIS Field Service Laboratories Selects GENE-UP Pathogenic E. coli Assay as Primary Method for Shiga Toxin-Producing E. coli Detection	07-02	CI
Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board	06-30	CI
BioMérieux: FDA waiver for new test	06-26	CF
BioMérieux Gets US FDA Clearance for Antimicrobial Susceptibility Testing System	06-21	MT
BioMérieux: FDA clearance for Vitek Reveal	06-21	CF
New purchases in MarketScreener's Europe portfolio	05-30
BioMérieux: head injury test cleared by the FDA	05-29	CF
BioMérieux: FDA clearance for Vidas TBI test	05-28	CF

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).

Employees

13,696

Sector

Medical Equipment, Supplies & Distribution

Calendar

29/10/2024 - Q3 2024 Sales and Revenue Call

More about the company